Pool J L
Baylor College of Medicine, Houston, Texas 77030.
Br J Clin Pract Suppl. 1994 May;74:8-12.
Hypertension often exists as part of a syndrome of cardiovascular, neuroendocrine and metabolic abnormalities. While antihypertensive pharmacotherapy has reduced the rates of stroke, congestive heart failure and renal failure, a disappointing benefit in terms of the reduction in coronary heart disease (CHD) mortality has been seen as a result of the adverse effects of some of the traditional antihypertensive agents on serum lipids and other factors. Doxazosin, a selective alpha 1-adrenoceptor inhibitor, is an effective antihypertensive agent with beneficial effects on an array of atherogenic risk factors. Treatment with doxazosin can lower blood pressure, reduce the levels of atherogenic lipids, increase the levels of cardioprotective lipids, reduce hyperinsulinaemia, insulin resistance and glucose intolerance, increase fibrinolysis, inhibit platelet aggregation, attenuate the adverse haemodynamic and haemostatic effects of smoking, and regress cardiac and smooth muscle hypertrophy. This unique combination of risk factor modifications should produce a reduction in CHD events.
高血压常作为心血管、神经内分泌和代谢异常综合征的一部分而存在。虽然抗高血压药物治疗已降低了中风、充血性心力衰竭和肾衰竭的发生率，但由于一些传统抗高血压药物对血脂和其他因素的不良影响，在降低冠心病（CHD）死亡率方面的益处令人失望。多沙唑嗪是一种选择性α1肾上腺素能受体抑制剂，是一种有效的抗高血压药物，对一系列致动脉粥样硬化危险因素具有有益作用。使用多沙唑嗪治疗可降低血压、降低致动脉粥样硬化脂质水平、提高心脏保护脂质水平、降低高胰岛素血症、胰岛素抵抗和葡萄糖不耐受、增加纤维蛋白溶解、抑制血小板聚集、减轻吸烟的不良血流动力学和止血作用，并使心脏和平滑肌肥大消退。这种对危险因素的独特综合改善应能减少冠心病事件的发生。
